Search

Your search keyword '"Ludwig-Sengpiel, A."' showing total 14 results
Start Over Author "Ludwig-Sengpiel, A." Publisher american thoracic society
14 results on '"Ludwig-Sengpiel, A."'

1. Effects of Single Inhaler Combinations of Extrafine Beclometasone Dipropionate, Formoterol Fumarate Plus Glycopyrronium (BDP/FF/G) and Extrafine Beclometasone Dipropionate Plus Formoterol Fumarate (BDP/FF) on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Author

Watz, H., primary, Kirsten, A.-M., additional, Ludwig-Sengpiel, A., additional, Mroz, R.M., additional, Charretier, R., additional, Varoli, G., additional, Vele, A., additional, Cortellini, M., additional, Krull, M., additional, and Galkin, D., additional

Published
2024
Full Text
View/download PDF

4. FOOTPRINTS® Study Methodology and Baseline Characteristics: A 3-Year Longitudinal Study to Phenotype Patients with COPD

Author

Frank Risse, Robert Mróz, Jens Vogel-Claussen, Abhya Gupta, Wim Janssens, M. Beck, Harald Koegler, H. Watz, J.D. Crapo, B. Langellier, A. Ludwig-Sengpiel, Claudia Diefenbach, A. Eleftheraki, Alice M Turner, and D.A. Lynch

Subjects
medicine.medical_specialty, Longitudinal study, COPD, business.industry, Internal medicine, Baseline characteristics, Study methodology, medicine, business, medicine.disease, Phenotype
Published
2020
Full Text
View/download PDF

5. FOOTPRINTS® Study Methodology and Baseline Characteristics: A 3-Year Longitudinal Study to Phenotype Patients with COPD

Author

Crapo, J.D., primary, Gupta, A., additional, Lynch, D.A., additional, Vogel-Claussen, J., additional, Watz, H., additional, Turner, A.M., additional, Mroz, R.M., additional, Janssens, W., additional, Ludwig-Sengpiel, A., additional, Beck, M., additional, Koegler, H., additional, Langellier, B., additional, Eleftheraki, A., additional, Risse, F., additional, and Diefenbach, C., additional

Published
2020
Full Text
View/download PDF

6. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

Author

David A. Lomas, Nicholas Locantore, Steven Pascoe, Andrea Ludwig-Sengpiel, Noushin Brealey, David A. Lipson, Ruby Birk, Chang-Qing Zhu, Helen Barnacle, Maggie Tabberer, and Rajat Mohindra

Subjects
Pulmonary and Respiratory Medicine, Budesonide, medicine.medical_specialty, COPD, medicine.drug_class, business.industry, Inhaler, Pulmonary disease, Critical Care and Intensive Care Medicine, medicine.disease, Fluticasone propionate, Surgery, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, 030228 respiratory system, chemistry, Internal medicine, medicine, Corticosteroid, 030212 general & internal medicine, Vilanterol, Formoterol, business, medicine.drug
Abstract

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.Objectives: We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD.Methods: The FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 μg/12 μg; Turbuhaler). A patient subgroup remained on blinded treatment for up to 52 weeks. Co–primary endpoints were change from baseline in trough FEV1 and in St. George’s Respiratory Questionnaire (SGRQ) total score at Week 24.Measurements and Main Results...

Published
2017
Full Text
View/download PDF

7. Safety and Tolerability of Four Weeks' Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III)

Author

Dave Singh, Rainard Fuhr, T. Litzenburger, A.-M. Kirsten, A. Ludwig-Sengpiel, M. Sarno, Abhya Gupta, C. Steimle-Goerttler, F. Pedersen, and X. Bai

Subjects
COPD, chemistry.chemical_compound, chemistry, Tolerability, business.industry, medicine.drug_class, medicine, Bradykinin, In patient, Pharmacology, medicine.disease, business, Receptor antagonist
Published
2019
Full Text
View/download PDF

9. Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease

Author

Andrea Ludwig-Sengpiel, Helen Barnacle, Ruby Birk, Noushin Brealey, Steven Pascoe, David A. Lomas, Chang-Qing Zhu, David A. Lipson, Nicholas Locantore, Rajat Mohindra, and Maggie Tabberer

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, MEDLINE, Pulmonary disease, Pneumonia, Critical Care and Intensive Care Medicine, medicine.disease, Bronchodilator Agents, Pulmonary Disease, Chronic Obstructive, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, medicine, Fluticasone, Humans, 030212 general & internal medicine, business, medicine.drug
Published
2018
Full Text
View/download PDF

10. Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease

Author

Lipson, David A., primary, Barnacle, Helen, additional, Birk, Ruby, additional, Brealey, Noushin, additional, Locantore, Nicholas, additional, Lomas, David A., additional, Ludwig-Sengpiel, Andrea, additional, Mohindra, Rajat, additional, Tabberer, Maggie, additional, Zhu, Chang-Qing, additional, and Pascoe, Steven J., additional

Published
2018
Full Text
View/download PDF

11. Reply to Suissa and Ariel: The FULFIL Trial

Author

Lipson, David A., primary, Barnacle, Helen, additional, Birk, Ruby, additional, Brealey, Noushin, additional, Locantore, Nicholas, additional, Lomas, David A., additional, Ludwig-Sengpiel, Andrea, additional, Mohindra, Rajat, additional, Tabberer, Maggie, additional, Zhu, Chang-Qing, additional, and Pascoe, Steven J., additional

Published
2018
Full Text
View/download PDF

12. Reply: 'FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease' and 'Triple Therapy in Chronic Obstructive Pulmonary Disease'

Author

David A. Lomas, Helen Barnacle, Steven Pascoe, Noushin Brealey, Ruby Birk, David A. Lipson, Maggie Tabberer, Nicholas Locantore, Chang-Qing Zhu, Andrea Ludwig-Sengpiel, and Rajat Mohindra

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, MEDLINE, Pulmonary disease, Critical Care and Intensive Care Medicine, Bronchodilator Agents, Unmet needs, Pulmonary Disease, Chronic Obstructive, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, medicine, Humans, 030212 general & internal medicine, Intensive care medicine, business
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results